ArticleImmunity2021
Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers.
0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 167 citations in OpenAlex.
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.Nature communications · 2026Article
- Systematic comparison of estimates of transcription factor activity by ATAC-seq and multiplexed reporter assays.Molecular systems biology · 2026Article
- Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.Nature communications · 2026Article
- SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells.EMBO reports · 2026Article
- Metadomain and metaloop genome interactions in mammalian T cells.Cell reports · 2026Article
- The Gut-Pancreas Axis in Type 1 Diabetes: Emerging Insights into Microbiota and Immune Interactions.International journal of molecular sciences · 2026Review
- CNS1-dependent regulatory T cells shape recovery from acute lung injury.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses.Molecular cancer therapeutics · 2026Article
- Next-Generation regulatory T cell therapies: Translational considerations for inflammatory bowel disease.Human immunology · 2026Review
- Engineered CD40-biosensor-expressing Treg cells as a cell therapy approach for inflammatory diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- CD38 endows local antigen-specific TNature immunology · 2026Article
- SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells.bioRxiv : the preprint server for biology · 2026Article
- Regulatory T Cell Heterogeneity in the Steady State and Tumor.Immune network · 2026Review
- Review
- Review
- Sheep placental extract ameliorates polycystic ovary syndrome in rats by regulating ERβ-mediated Treg cells via the TGF-β1/Smad3 signaling pathway.Frontiers in immunology · 2026Article
- Immunomodulatory roles of regulatory T cells in cutaneous wound healing: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
- Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity.Frontiers in immunology · 2026Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 5 institutions in 1 country.
Michael DelacherRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany; Institute of Immunology, University Medical Center Mainz, 55131 Mainz, Germany; Research Centre for Immunotherapy, University Medical Center Mainz, 55131 Mainz, Germany.
Malte SimonFaculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Lieke SanderinkRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Agnes Hotz-WagenblattCore Facility Omics IT and Data management (ODCF), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Marina WuttkeRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Kathrin SchambeckRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Lisa SchmidleithnerRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Sebastian BittnerRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Asmita PantRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Uwe RitterRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Thomas HehlgansRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany.
Dania RiegelRegensburg Center for Interventional Immunology (RCI).
Verena SchneiderUniversity Hospital Würzburg, Department of Tissue Engineering and Regenerative Medicine TERM, 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research ISC, Translational Center for Regenerative Therapies TLZ-RT, 97082 Würzburg, Germany.
Florian Kai Groeber-BeckerUniversity Hospital Würzburg, Department of Tissue Engineering and Regenerative Medicine TERM, 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research ISC, Translational Center for Regenerative Therapies TLZ-RT, 97082 Würzburg, Germany.
Andreas EigenbergerDepartment of Plastic, Hand- and Reconstructive Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Claudia GebhardRegensburg Center for Interventional Immunology (RCI).
Nicholas StriederRegensburg Center for Interventional Immunology (RCI).
Alexander FischerRegensburg Center for Interventional Immunology (RCI); Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany.
Michael RehliRegensburg Center for Interventional Immunology (RCI); Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany.
Petra HoffmannRegensburg Center for Interventional Immunology (RCI); Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany.
Matthias EdingerRegensburg Center for Interventional Immunology (RCI); Department of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany.
Till StrowigDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany; Hannover Medical School, 30625 Hannover, Germany; RESIST, Cluster of Excellence 2155, Hannover Medical School, 30625 Hannover, Germany.
Jochen HuehnDepartment of Experimental Immunology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany; RESIST, Cluster of Excellence 2155, Hannover Medical School, 30625 Hannover, Germany.
Christian SchmidlRegensburg Center for Interventional Immunology (RCI).
Jens M WernerDepartment of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Lukas PrantlDepartment of Plastic, Hand- and Reconstructive Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Benedikt BrorsDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Charles D ImbuschDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Markus FeuererRegensburg Center for Interventional Immunology (RCI); Chair for Immunology, University Regensburg, 93053 Regensburg, Germany. Electronic address: markus.feuerer@ukr.de.
University Hospital Regensburg · DEGerman Cancer Research Center · DEMedizinische Hochschule Hannover · DEUniversitätsklinikum Würzburg · DEJohannes Gutenberg University Mainz · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Murine regulatory T (Treg) cells in tissues promote tissue homeostasis and regeneration. We sought to identify features that characterize human Treg cells with these functions in healthy tissues. Single-cell chromatin accessibility profiles of murine and human tissue Treg cells defined a conserved, microbiota-independent tissue-repair Treg signature with a prevailing footprint of the transcription factor BATF. This signature, combined with gene expression profiling and TCR fate mapping, identified a population of tissue-like Treg cells in human peripheral blood that expressed BATF, chemokine receptor CCR8 and HLA-DR. Human BATF
Indexed as
AdultAnimalsBasic-Leucine Zipper Transcription FactorsCell DifferentiationCell LineChromatinFemaleGene Expression ProfilingGene Expression RegulationHaCaT CellsHumansMaleMiceMice, Inbred C57BLMiddle AgedReceptors, CCR8Basic-Leucine Zipper Transcription FactorsChromatinReceptors, CCR8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.